TY - JOUR
T1 - Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis
AU - Boccia, Stefania
AU - Ricciardi, Gualtiero
AU - Manzoli, L
AU - Flacco, Me
AU - D’Andrea, E
AU - Panic, N
AU - Marzuillo, C
AU - Siliquini, R
AU - Villari, P
AU - Ioannidis, Jp
PY - 2015
Y1 - 2015
N2 - Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
AB - Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
KW - cardiovascular diseases
KW - meta-analysis
KW - cardiovascular diseases
KW - meta-analysis
UR - http://hdl.handle.net/10807/70743
M3 - Conference article
VL - 25
SP - 74
EP - 74
JO - European Journal of Public Health
JF - European Journal of Public Health
SN - 1101-1262
T2 - 8th European Public Health Conference
Y2 - 14 October 2015 through 17 October 2015
ER -